EUVIMEDEUVIMED entdecken
Open Access

Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma

Miriam Ricanati, Ucalene Harris, Neil M Neumann, Banu Farabi, Nicholas Kurtansky, Anthony Rossi, Chih-Shan J Chen, Melissa P Pulitzer, Milind Rajadhyaksha, Stephen Dusza, Ashish Dhir, Manu Jain

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.269428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Miriam Ricanati und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Poly (ADP-Ribose) Polymerase-1, Skin Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Basal cell carcinoma (BCC), the most common skin cancer, typically requires biopsy for definitive diagnosis. Reflectance confocal microscopy is a noninvasive rule-out test, but the lack of nuclear contrast in BCC often leads to missed diagnoses. Our previous research in ex vivo human skin indicated that PARPi-FL, a poly(adenosine diphosphate ribose) polymerase 1 (PARP1) inhibitor-targeted fluorescent contrast agent, penetrated intact skin when applied topically and improved the diagnosis of BCC compared with reflectance confocal microscopy alone. This study refined PARPi-FL's concentration and application timing to assess its detectability, safety, and feasibility for topical use in clinics and investigated its potential to distinguish BCC from nonmalignant clinical mimickers.

Methods

We assessed PARP1 expression in 86 BCCs and 76 nonmalignant mimickers via immunohistochemistry. PARPi-FL (10 μM) permeability on ex vivo human skin was evaluated using a fluorescent confocal microscope (FCM) after 5 min compared with the previously evaluated times of 10-30 min. We evaluated the detectability of PARPi-FL's fluorescent signal (10 μM; 5 and 30 min) via FCM through intact skin in excised human BCC tumors and compared it with the signal in 4 benign lesions. FCM imaging was conducted in anesthetized tumor-bearing B6 K5-Gli2 mice to evaluate topical application with gauze, simulating in vivo human imaging. Quantitative measurements of FCM signal intensities were taken with varying PARPi-FL concentrations (>10 μM) at 5 min. Systemic and cutaneous toxicity were assessed in SKH1-Hrhr mice and Yorkshire pigs.

Results

PARP1 was overexpressed in BCC lesions compared with nonmalignant lesions. PARPi-FL penetrated intact human skin and labeled dermal structures within 2-5 min. A strong fluorescent signal from BCC lesions was detectable through the skin surface to a depth of approximately 100 µm after 5 min, whereas benign lesions showed lower and more variable signals. PARPi-FL application using gauze proved effective, with detectable signals in tumor-bearing mice. Increasing the concentration and reducing application time enhanced the nuclear fluorescent signal. No serious toxicity was observed in preclinical species.

Conclusion

PARPi-FL is a fluorescent molecular contrast agent that has shown preclinical safety and translational potential for use in topical application for noninvasive BCC diagnosis. Its diagnostic accuracy and safety in humans require validation in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaPoly (ADP-Ribose) Polymerase-1Skin NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsContrast MediaTranslational Research, BiomedicalFluorescent DyesHumansAnimalsMiceFemaleMaleMicroscopy, Confocal

Stichwörter der Autor:innen

PARPi-FL topical safetySKH1-Hrhr miceYorkshire pigsbasal cell carcinomabenign lesionstranslational potential

Substanzen

Poly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsContrast MediaFluorescent DyesPARP1 protein, human

Autor:innen und Institutionen

  • Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Dermatology, New York Medical College, Valhalla, New York; and.
  • Office of Entrepreneurship and Commercialization, Memorial Sloan Kettering Cancer Center, New York, New York jainm@mskcc.org dhira@mskcc.org.
  • Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York; jainm@mskcc.org dhira@mskcc.org.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ricanati, M., Harris, U., Neumann, N. M., Farabi, B., Kurtansky, N., Rossi, A., Chen, C. J., Pulitzer, M. P., Rajadhyaksha, M., Dusza, S., Dhir, A., & Jain, M. (2025). Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269428

Vancouver

Ricanati M, Harris U, Neumann NM, Farabi B, Kurtansky N, Rossi A, et al. Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269428

BibTeX
@article{Ricanati2025,
  author = {Ricanati, Miriam and Harris, Ucalene and Neumann, Neil M and Farabi, Banu and Kurtansky, Nicholas and Rossi, Anthony and Chen, Chih-Shan J and Pulitzer, Melissa P and Rajadhyaksha, Milind and Dusza, Stephen and Dhir, Ashish and Jain, Manu},
  title = {Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.269428}
}
Kostenlos starten →